Cullinan Therapeutics (CGEM) Net Cash Flow (2020 - 2026)

Cullinan Therapeutics' Net Cash Flow history runs 7 years deep, the most recent figure standing at -$13.3 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 108.68% year-over-year to -$13.3 million; the TTM figure through Mar 2026 stood at -$1.6 million (down 164.85% YoY), while the FY2025 annual figure was $5.3 million, up 134.53% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$13.3 million, up from -$15.0 million in the prior quarter.
• The five-year high for Net Cash Flow was $277.4 million in Q2 2022, with the low at -$110.9 million in Q3 2022.
• The 5-year median for Net Cash Flow is -$12.9 million (2024), against an average of $900411.8.
• The sharpest annual moves came in 2023 and 2025: Net Cash Flow slumped 308.17% in 2023, then surged 335.89% in 2025.
• Cullinan Therapeutics' Net Cash Flow stood at -$86.5 million in 2022, then surged by 138.83% to $33.6 million in 2023, then sank by 156.81% to -$19.1 million in 2024, then advanced by 21.37% to -$15.0 million in 2025, then advanced by 11.68% to -$13.3 million in 2026.
• Business Quant data shows CGEM's Net Cash Flow at -$13.3 million in Q1 2026, -$15.0 million in Q4 2025, and $30.5 million in Q3 2025.